NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Nuvectis Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$18.94+0.34 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $444.64M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$12.77 (+207.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $444.64M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 48.96
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$27.85M
- EPS, diluted
- -$1.32
- Book value per share
- $0.39
- Diluted shares
- 23M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
-$28.87M
Net income
-$27.85M
EPS, diluted
-$1.32
Reported periodTrailing twelve months